ArticleJournal, genetic engineering & biotechnology2026
Enhancement and balance of 1,4-butanediamine biosynthesis in Escherichia coli based on modular metabolic engineering.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1,4-Butanediamine is an important raw material for the synthesis of engineering plastics such as Polyamide 46 with excellent performance, which is widely used in automotive, electronics and machinery manufacturing industries. In this study, Escherichia coli BL21(DE3) was used as the starting strain to systematically modify the 1,4-butanediamine biosynthesis pathway using a modular strategy. 1,4-Butanediamine biosynthesis was re-divided into two modules: 1,4-butanediamine production module and α-ketoglutaric acid production module. By controlling the expression intensity of genes pykF, ppc, aceEF, gltA, icdA and gdhA, argD, argCB, argJ, ODC10, a recombinant producing 1,4-butanediamine strain PKT was obtained, achieving a yield of 862.82 mg/L of 1,4-butanediamine, which increased 8.62-fold compared to that of Escherichia coli BL21(DE3). Then, the fermentation medium of PKT strain was optimized. After 24 h of fermentation, the yield of 1,4-butanediamine reached 1843.60 mg/L, representing a 16.23-fold increase over the original strain. Furthermore, non-target metabolomics analysis was used to analyze the changes of metabolites during the efficient synthesis of 1,4-butanediamine by the recombinant strain PKT. The results showed that the total number of differential metabolites detected was 653. Differential metabolite pathway analysis showed that there were 9 differential metabolites in the 1,4-butanediamine synthesis pathway, with 5 involved in its synthesis pathway and 4 in its degradation branch. These differences in metabolites provide a theoretical basis for the modification of recombinant strains. The green production of 1,4- butanediamine by microbial cell factories through fermentation is the future direction. This research provides a theoretical guidance of building high yield 1,4-butanediamine engineering strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.